XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Xeris Biopharma Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$10.95+0.64 (+6.21%)

Close on Oct 19, 2026

Community

Notes and questions about Xeris Biopharma from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Xeris Biopharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is XERS.

Revenue growth36.3% · median 24.3%

Gross margin86.6% · median 91.3%

Operating margin10.9% · median 15.4%

Net margin-5.1% · median 12.0%

Advertisement
300 × 250